deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01663402

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Sponsor: Regeneron Pharmaceuticals

Conditions Atherosclerotic Cardiovascular Disease
Interventions Alirocumab LMT Placebo
Updated 15 times since 2017 Last updated: Mar 15, 2019 Started: Oct 31, 2012 Primary completion: Jan 23, 2018 Completion: Jan 23, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Atherosclerotic Cardiovascular Disease, this trial is completed. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 15 data snapshots since 2012. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Feb 2018 · 11 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Jan 2021 · 21 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Mar 2026 · 3 months · monthly snapshot~Mar 2026 – present · 5 months · monthly snapshot

Change History

15 versions recorded

  1. Mar 2026 — Present [monthly]

    Completed PHASE3

  2. Dec 2025 — Mar 2026 [monthly]

    Completed PHASE3

  3. Nov 2025 — Dec 2025 [monthly]

    Completed PHASE3

  4. Oct 2025 — Nov 2025 [monthly]

    Completed PHASE3

  5. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

▶ Show 10 earlier versions

  1. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Apr 2019 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jun 2018 — Apr 2019 [monthly]

    Completed PHASE3

  6. Mar 2018 — Jun 2018 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  7. Feb 2018 — Mar 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Mar 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Regeneron Pharmaceuticals
  • Sanofi
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aabenraa, Denmark , Aachen, Germany , Aalborg, Denmark , Aalst, Belgium , Aarhus N, Denmark , Adana, Turkey (Türkiye) , Adrogué, Argentina , Afula, Israel , Aguascalientes, Mexico , Ahmedabad, India and 960 more locations